Inside Pfizer’s $100 billion blockbuster offer for AstraZeneca. Is a more favorable tax rate in Britain the real reason behind the deal?
For this story and more tune in tonight.
Hosts
Top Stories from CNBC- Apple CEO Tim Cook's new cash bonus sweetener not tied to bigger sales or profits
- House probes security and intelligence failures in deadly U.S. Capitol attack
- Democratic governors accuse Trump administration of misleading them about vaccine stockpile
- These entrepreneurs want a second PPP loan. What you should know if you're applying for more money
- 'I don’t see anything on the horizon that can stop the growth of the ETF market,' Invesco official says. Here are her 2021 predictions
